Physician profile
Christina Teresa Campbell
NPI 1861980443
$14,936.09
in general payments reported to CMS, 2019-2025
19 companies · $2,107 in 2025
The $2,107 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,981 · 2022: $3,466 · 2023: $3,512 · 2024: $2,871 · 2025: $2,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,479 · Education: $10.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,478.92 |
| Education | $10.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,134.04 | 2021-2025 | Biktarvy, Veklury |
| Viiv Healthcare Company | $3,668.62 | 2021-2025 | Cabenuva, Dovato, Apretude |
| Merck Sharp & Dohme LLC | $1,315.36 | 2021-2025 | Pifeltro, Dificid, Zerbaxa |
| Janssen Biotech, INC. | $1,183.41 | 2021-2023 | Symtuza |
| Insmed, INC. | $1,040.07 | 2021-2025 | Arikayce |
| Abbvie INC. | $1,033.35 | 2021-2025 | |
| Melinta Therapeutics, LLC | $766.59 | 2021-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Theratechnologies INC. | $571.33 | 2021-2024 | Egrifta, Trogarzo |
| Paratek Pharmaceuticals, INC. | $486.62 | 2021-2025 | Nuzyra |
| Shionogi INC | $390.51 | 2021-2025 | Fetroja |
| Janssen Scientific Affairs, LLC | $69.19 | 2022-2023 | Symtuza |
| Vyera Pharmaceuticals, LLC | $64.90 | 2021 | |
| Emd Serono, INC. | $64.89 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.55 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $26.23 | 2025 | Novachor |
| Pacira Pharmaceuticals Incorporated | $23.40 | 2022 | |
| La Jolla Pharmaceutical Company | $21.37 | 2022 | |
| Mayne Pharma Commercial LLC | $18.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.